Trials / Completed
CompletedNCT00882882
To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions
A Relative Bioavailability Study of Metformin HCL 500 mg XR Tablets Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 19 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC | |
| DRUG | Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC | |
| DRUG | GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb | |
| DRUG | GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb |
Timeline
- Start date
- 2001-06-01
- Primary completion
- 2001-06-01
- Completion
- 2001-06-01
- First posted
- 2009-04-17
- Last updated
- 2017-03-29
Source: ClinicalTrials.gov record NCT00882882. Inclusion in this directory is not an endorsement.